Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript09/12/2025
Economy & Business 1 Min ReadMarvell: The Bull Case Revolves Around Optics, Not ASICsBy Admin08/12/20251 Min ReadMarvell: The Bull Case Revolves Around Optics, Not ASICs
